The Double-Edged Sword: Legumain as a Context-Dependent Mediator and Therapeutic Target in Cancer and Cardiovascular Disease
Siarhei A. Dabravolski, Gulalek A. Babayeva, Daria D. Borodko, Ulyana V. Rozhkova, Stanislav A. Antonov, Aleksandra S. Utkina, Maria O. Nerush · 2026
Read The Double-Edged Sword: Legumain as a Context-Dependent Mediator and Therapeutic Target in Cancer and Cardiovascular Disease by Siarhei A. Dabravolski, Gulalek A. Babayeva, Daria D. Borodko, Ulyana V. Rozhkova, Stanislav A. Antonov, Aleksandra S. Utkina, Maria O. Nerush (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13605910.txt.
Description
Siarhei Dabravolski and co-authors review a protein-cutting enzyme named legumain in a 2026 paper. Long known for its housekeeping work inside cells, the enzyme now shows up in many parts of the cell and in many states of disease.
The review joins two fields that rarely meet: cancer and heart and vessel disease. In cancer the enzyme helps tumors grow, spread, and hide from the body's defenses, and it may serve as a sign of how a case will go. In vessel disease it feeds wall buildup, high pressure, and poor repair of the heart. Drugs that aim at it are still at an early stage. The authors note gaps, such as the lack of shared lab tests, and frame the enzyme as a dial that can help or harm.
Catalog record
| CREATOR | Siarhei A. Dabravolski, Gulalek A. Babayeva, Daria D. Borodko, Ulyana V. Rozhkova, Stanislav A. Antonov, Aleksandra S. Utkina, Maria O. Nerush |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 51 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |